NCT06819228View on ClinicalTrials.gov

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 17, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2029

Conditions
HNSCCHNSCC,Larynx, Pharynx and Oral CavitySCC - Squamous Cell Carcinoma
Interventions
DRUG

Panitumumab IRDye 800

Study participation would last approximately 60 days from screening to follow-up visits. Participants dose of Panitumumab would be based on weight and Panitumumab IRDye800 is dosed the same for all participants.

Trial Locations (1)

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt-Ingram Cancer Center

OTHER